The Biotechnology Program has also expanded its STEM outreach efforts to include a summer internship program for high school ...

Data update from ongoing TNG462 Phase 1/2 monotherapy trial expected 2H 2025 - - Combination trial of TNG462 + Revolution Medicines RAS(ON) inhibitors on track for enrollment 2Q 2025 - - Cash position ...

For example, although... Company to Host Conference Call, May 13, 2025 at 4:30 p.m. ETSAN DIEGO, May 06, 2025 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company ...

The poster presentation, based on a post-hoc analysis ... but after 96 weeks it was similar. For example, qFibrosis® analysis of Week 96 biopsy samples from 50mg EFX patients (N=26) revealed ...

All Environmental Studies majors participate in public poster presentations as part of the thesis process. A poster session is organized for Wednesday in the last week of the fall and winter semesters ...

Successful presentation of six posters at the AACR annual meeting ... ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to ...

Proof-of-mechanism has been established for TNG260 based on pharmacodynamic data from on-treatment patient biopsies, with ...

Stylus Medicine is developing transformative in vivo genetic medicines to unlock cures. Stylus combines engineered recombinases with non-viral delivery to specifically encode therapeutics. The ...

The Harvard Center for International Development (CID) is a research center working across the University and a global network of researchers and practitioners to build an international pool of talent ...

Find out how we're targetting global challenges including future manufacturing, biomedical engineering, energy, security and urban energy systems ...